Özkan Yalkinoglu

488 total citations
22 papers, 220 citations indexed

About

Özkan Yalkinoglu is a scholar working on Rheumatology, Immunology and Molecular Biology. According to data from OpenAlex, Özkan Yalkinoglu has authored 22 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Rheumatology, 6 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Özkan Yalkinoglu's work include Systemic Lupus Erythematosus Research (6 papers), Malaria Research and Control (4 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Özkan Yalkinoglu is often cited by papers focused on Systemic Lupus Erythematosus Research (6 papers), Malaria Research and Control (4 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Özkan Yalkinoglu collaborates with scholars based in Germany, Switzerland and United States. Özkan Yalkinoglu's co-authors include Christoph Gerdes, Stefan Wohlfeil, S. Effert, Raimund Erbel, P. Schweizer, Jürgen Meyer, W. Krebs, Claude Oeuvray, Deon Bezuidenhout and Orestis Papasouliotis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Arteriosclerosis Thrombosis and Vascular Biology and Annals of Oncology.

In The Last Decade

Özkan Yalkinoglu

22 papers receiving 215 citations

Peers

Countries citing papers authored by Özkan Yalkinoglu

Since Specialization

Citations

This map shows the geographic impact of Özkan Yalkinoglu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Özkan Yalkinoglu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Özkan Yalkinoglu more than expected).

Fields of papers citing papers by Özkan Yalkinoglu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Özkan Yalkinoglu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Özkan Yalkinoglu. The network helps show where Özkan Yalkinoglu may publish in the future.

Co-authorship network of co-authors of Özkan Yalkinoglu

This figure shows the co-authorship network connecting the top 25 collaborators of Özkan Yalkinoglu. A scholar is included among the top collaborators of Özkan Yalkinoglu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Özkan Yalkinoglu. Özkan Yalkinoglu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Sathej Gopalakrishnan, Özkan Yalkinoglu, (unknown), Hong Lü, Kosalaram Goteti, Axel Krebs‐Brown, (unknown), Ulrike Gradhand, Markus Fluck, (unknown), Jennifer Dong, Karthik Venkatakrishnan	13
2	Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues 2024 ·Proceedings of the National Academy of Sciences ·(unknown), Sonia Schuepbach‐Mallepell, (unknown), Laure Willen, Christine Kowalczyk‐Quintas, Chantal Desponds, (unknown), Michele Vigolo, (unknown), Olivier Donzé, Sanjiv A. Luther, Özkan Yalkinoglu, (unknown), Pascal Schneider	11
3	Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates 2023 ·Investigational New Drugs ·Özkan Yalkinoglu, (unknown), Axel Krebs‐Brown, Claudia S. Vetter, (unknown), Dominique Perrin, (unknown), (unknown), (unknown), (unknown), (unknown), Rainer Strotmann	5
4	Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models 2023 ·Malaria Journal ·Xiaoyan Yin, Ying Li, (unknown), Özkan Yalkinoglu, Deon Bezuidenhout, (unknown), James McCarthy, Louise Marquart, Claude Oeuvray	1
5	Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Özkan Yalkinoglu, Colm Farrell, Pascal Girard, (unknown), Orestis Papasouliotis	4
6	Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside 2022 ·Malaria Journal ·Akash Khandelwal, (unknown), Paula M. Alves, Lassina Badolo, Catarina Brito, Christoph Fischli, Diana Fontinha, Claude Oeuvray, Miguel Prudêncio, Matthias Rottmann, Justin Wilkins, Özkan Yalkinoglu, (unknown), Thomas Spangenberg	8
7	Kinetics of free and ligand-bound atacicept in human serum 2022 ·Frontiers in Immunology ·(unknown), (unknown), Orestis Papasouliotis, (unknown), Laure Willen, Olivier Donzé, Özkan Yalkinoglu, Pascal Schneider	2
8	Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review 2021 ·BMC Infectious Diseases ·Workineh Shibeshi, (unknown), Özkan Yalkinoglu, (unknown), Ephrem Engidawork, Claude Oeuvray	7
9	Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study 2021 ·The Lancet Infectious Diseases ·James McCarthy, Özkan Yalkinoglu, (unknown), (unknown), Claude Oeuvray, (unknown), Deon Bezuidenhout, Marla J. Giddins, Satish K. Dhingra, David A. Fidock, Louise Marquart, Lachlan Webb, Xiaoyan Yin, Akash Khandelwal, (unknown)	42
10	Comparison of POC-CCA with Kato-Katz in Diagnosing Schistosoma mansoni Infection in a Pediatric L-Praziquantel Clinical Trial 2021 ·Frontiers in Tropical Diseases ·(unknown), Eliézer K. N’Goran, Mamadou Ouattara, (unknown), Nana R. Diakité, (unknown), (unknown), (unknown), Özkan Yalkinoglu, Eric Huber, Deon Bezuidenhout, (unknown), Brooke Hayward	7
11	1257P Effect of hepatic impairment on tepotinib pharmacokinetics 2021 ·Annals of Oncology ·Thomas Marbury, Özkan Yalkinoglu, (unknown), Axel Krebs‐Brown, (unknown), Andreas Port, Rainer Strotmann	1
12	Efficacy and Safety of New Orodispersible Tablet Formulations of Praziquantel (Racemate and L-Praziquantel) in Schistosoma mansoni-Infected Preschool-Age Children and Infants: A Randomized Dose-Finding Phase 2 Study 2021 ·Frontiers in Tropical Diseases ·Eliézer K. N’Goran, Özkan Yalkinoglu, (unknown), (unknown), Brooke Hayward, (unknown), Deon Bezuidenhout, Eric Huber, (unknown), Mamadou Ouattara, (unknown)	4
13	BAFF 60-mer, and Differential BAFF 60-mer Dissociating Activities in Human Serum, Cord Blood and Cerebrospinal Fluid 2020 ·Frontiers in Cell and Developmental Biology ·(unknown), Edgar Meinl, Hermann Eibel, Laure Willen, Olivier Donzé, O. Distl, Holm Schneider, Daniel E. Speiser, Dimitrios Tsiantoulas, Özkan Yalkinoglu, Eileen T. Samy, Pascal Schneider	11
14	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects 2019 ·European Journal of Drug Metabolism and Pharmacokinetics ·(unknown), Wolfgang Uhl, (unknown), Orestis Papasouliotis, Özkan Yalkinoglu	10
15	Bioavailability of tepotinib: Impact of omeprazole and food 2019 ·Annals of Oncology ·Rainer Strotmann, Josef G. Heuer, (unknown), Axel Krebs‐Brown, (unknown), Özkan Yalkinoglu	3
16	Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates 2019 ·Annals of Oncology ·Özkan Yalkinoglu, Josef G. Heuer, (unknown), Axel Krebs‐Brown, Rainer Strotmann	6
17	No interactions between heparin and atacicept, an antagonist of B cell survival cytokines 2019 ·British Journal of Pharmacology ·Christine Kowalczyk‐Quintas, (unknown), Laure Willen, Michaela Golob, Sonia Schuepbach‐Mallepell, (unknown), (unknown), Michele Vigolo, Hervé Broly, Eileen T. Samy, Özkan Yalkinoglu, Pascal Schneider	7
18	Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris®) in Pituitary-Suppressed Healthy Women 2018 ·Frontiers in Endocrinology ·(unknown), Özkan Yalkinoglu, (unknown)	1
19	AB0519 The Pharmacokinetics and Safety Profiles of Atacicept After Single Subcutaneous Doses in Healthy Japanese and Caucasian Volunteers 2015 ·Annals of the Rheumatic Diseases ·(unknown), Michaela Golob, (unknown), Orestis Papasouliotis, Wolfgang Uhl, Özkan Yalkinoglu	1
20	Comparison of the Effects of the Thrombin Inhibitor r-Hirudin in Four Animal Models of Neointima Formation After Arterial Injury 1996 ·Arteriosclerosis Thrombosis and Vascular Biology ·Christoph Gerdes, (unknown), Özkan Yalkinoglu, Stefan Wohlfeil	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact